Peter Libby: Mast Cells in Cardiovascular Disease
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Mass General Brigham Hospital, shared a post on LinkedIn:
“Every leukocyte class shall have its day in atherosclerosis. With an international team, we summarize the current evidence supporting mechanisms by which mast cells can participate in this disease. Inflammation has many faces, and reaginic antibody (IgEs) can link adaptive to innate immunity unleashing a multitude of mast cell mediators that can modulate arterial and microvascular biology.”
Title: Mast cells in cardiovascular disease: Fibrosis, angiogenesis and atherogenesis
Authors: Gabriel Bueno, Ilze Bot, Anish A. Kanhai, Roberta Stilhano, Peter Libby, Guido R.Y. De Meyer, Leonardo Martin
Stay informed with Hemostasis Today.
-
Jun 8, 2026, 14:13Harshal Kale: From Personal Journey to Global Advocacy
-
Jun 8, 2026, 14:11Aryabhatta Sadhu: Evidence-Based Restrictive Transfusion and Patient Blood Management
-
Jun 8, 2026, 14:05Burhan Ullah: The Expanding Role of Hematology Analyzers in Disease Detection and Monitoring
-
Jun 8, 2026, 13:502025 EHA Annual Report Is Now Online
-
Jun 8, 2026, 13:49Lovish Garg: Advances in Endovascular Treatment for Deep Vein Thrombosis
-
Jun 8, 2026, 13:39Tasbeeh Ahmed: Contemporary Treatment Strategies for Chronic Venous Disease
-
Jun 8, 2026, 13:35Wolfgang Miesbach: Translating Gene Therapy into Haemophilia Care at EHA 2026
-
Jun 8, 2026, 13:27Emile Hung: Why Nutrition Should Be Central to Vascular Disease Prevention
-
Jun 8, 2026, 12:21William Aird: Developing Patient-Facing Educational Material for The Blood Project